TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06546514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breath Exercise
Description: It was provided by the researcher that the patients performed 5 repetitions of 10 breathing exercises every 3 hours a day, between 09:00am and 21:00pm, 1 day before the surgery, on the day of surgery and on the first day after surgery.
Study: NCT05155488

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT06541340

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified strategy
Description: Modified preoperative biliary drainage strategy with prealbumin as the main indicator

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional strategy
Description: Traditional preoperative biliary drainage strategy with total bilirubin as the main indicator
Study: NCT05624697

Intervention type: PROCEDURE
Group type: OTHER
Intervention: sticky bone housed in PEEK Shell
Description: Patient specific Sticky Bone/Implant housing PEEK shell in Anterior Atrophic Maxilla
Study: NCT05998317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: At-night Dexamethasone
Description: Patients in the intervention group will receive intravenous 8 mg dexamethasone at night before surgery. The time of dexamethasone administration will be recorded. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: At-induction Dexamethasone
Description: Patients in the control group will receive intravenous 8 mg dexamethasone just before or at the induction of anesthesia. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.
Study: NCT05612802

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: IGF-1
Description: We need to diagnose acute kidney injury in the early postoperative period. The markers examined so far do not provide enough information to diagnose acute kidney injury early. For this reason, many different biomarkers are used in the early diagnosis of acute kidney injury in many parts of the world. Thanks to our research, we can recognise the development of acute kidney injury at an early stage and determine whether a previously unused biomarker (IGF-1) is effective in the early diagnosis of acute kidney injury.
Study: NCT05103839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gentle Yoga
Description: Yoga classes are twice a week for up to 10 weeks with a trained yoga instructor at a location in the community. Classes will last up to 75 minutes.
Study: NCT06068283

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LOTUS mHealth Intervention Group
Description: A mobile, WebApp-based intervention comprised of tips for HIV prevention, a community wall for peer interaction and support, HIV prevention monitoring and reminders, guided discussions with a health care professional, a resource database, and a personalized profile. Intervention components are designed to promote HIV prevention service use, reduce stigma and improve social support, coping strategies, and positive affect.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LOTUS Control Group
Description: Access to an information-only website with content on HIV transmission, PrEP, harm reduction, and resources for women.
Study: NCT05563506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Kids +
Description: Three times a week for 30 weeks.
Study: NCT05008393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PJS-539 Dose 1
Description: Patients will receive PJS-539 dose 1 daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PJS-539 Dose 2
Description: Patients will receive PJS-539 Dose 2 daily for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo daily for 10 days.
Study: NCT05949424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Starting dose of 200mg 2dd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Starting dose of 10mg 1dd.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Starting dose of 25mg 1dd 28/42 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Starting dose of 75mg 1dd 21/28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Starting dose of 200mg 1dd.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: Starting dose of 300mg 2dd.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: Starting dose of 20mg 1dd for RCC or endometrial carcinoma, starting dose of 24mg 1dd for thyroid carcinoma.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: Starting dose of 50mg 1dd 28/42 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: Starting dose of 125mg 1dd 21/28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pazopanib
Description: Starting dose of 800mg 1dd.
Study: NCT05031637

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: treatment of BP by using night-time BP
Description: titration of BP medications to target according to night-time SBP

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: treatment of BP by using daytime BP
Description: titration of BP medications to target according to daytime SBP
Study: NCT05388149

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Neratinib administered as 40mg tablets
Study: NCT04597099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micronized progesterone
Description: oral micronized progesterone suspension, 100 mg oral dose at 0800 during each study admission

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Micronized progesterone
Description: oral micronized progesterone suspension, 100 mg oral dose at 0800 during each study admission

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Flutamide, 250 mg taken orally twice daily for four weeks before study admission.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol patch
Description: Two 0.1 mg/day transdermal estradiol patches will be applied 3 days prior to each inpatient admission; on the morning of study admission, these two patches will be removed and immediately replaced with two new 0.1 mg/day patches.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estradiol patch
Description: Two 0.1 mg/day transdermal estradiol patches will be applied 3 days prior to each inpatient admission; on the morning of study admission, these two patches will be removed and immediately replaced with two new 0.1 mg/day patches.
Study: NCT05243537

Intervention type: OTHER
Intervention: ECG (diagnostic)
Description: ECG collection (once, at rest), in both cases and controls
Study: NCT04998097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: Investigators adopted the iTBS protocol which follows the standard TBS protocols, with 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 80% motor threshold. In each session, a 2-s train of bursts will be repeated every 10 s for a total of 570 s (1800 pulses) to the left dorsolateral prefrontal cortex (DLPFC). TBS sessions will be scheduled daily in a 5-day sequence, for a total of 10 sessions in 2 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham repetitive transcranial magnetic stimulation (rTMS)
Description: no stimulation, Sham TBS sessions will be scheduled daily in a 5-day sequence, for a total of 10 sessions in 2 weeks.
Study: NCT05200117

Intervention type: DEVICE
Intervention: Pregnolia System
Description: The cervical stiffness is measured with the Pregnolia System three times over a two-day period.

Intervention type: DEVICE
Intervention: Pregnolia System
Description: The cervical stiffness is measured with the Pregnolia System three times over a two-day period.
Study: NCT06507904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osivelotor
Description: A medicine to treat sickle cell disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osivelotor
Description: A medicine to treat sickle cell disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osivelotor
Description: A medicine to treat sickle cell disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osivelotor
Description: A medicine to treat sickle cell disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osivelotor
Description: A medicine to treat sickle cell disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osivelotor
Description: A medicine to treat sickle cell disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osivelotor
Description: A medicine to treat sickle cell disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osivelotor
Description: A medicine to treat sickle cell disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osivelotor
Description: A medicine to treat sickle cell disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osivelotor
Description: A medicine to treat sickle cell disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osivelotor
Description: A medicine to treat sickle cell disease.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Famotidine is a marketed medicine which decreases the amount of acid made in the stomach and is used to prevent and treat heartburn.
Study: NCT04633239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study: NCT04684589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 20 MG
Description: Tadalafil is an FDA approved, clinically-available drug that inhibits the enzyme phosphodiesterase type 5A (PDE5). Subjects who are randomized to this arm will be provided with 20mg of Tadalafil to take every day for 12 weeks, beginning at their baseline visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in this arm will be provided with 20mg Placebo to take every day for 12 weeks, beginning at their baseline visit.
Study: NCT06583447

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Calorie-restricted diet (CRD)
Description: Standardized lifestyle interventions for all obese children and their parents will be constructed by endocrinologists and dietitians to increase physical activity and healthy eating habits. Physical activity interventions include decreasing time spent in sedentary activities, increasing the amount of physical activity, and recommending at least 60 minutes of moderate-intensity exercise per day. Individualized dietary counseling is provided to address the comorbidities in obese children.~Based on the standardized lifestyle intervention, the study subjects in the control group will be treated with CRD. Total daily energy intake will be restricted to 80% of the energy requirement for each age group in the Dietary Reference Intakes of Nutrients for Chinese Residents DRIs 2013. A daily food diary will be kept for at least one weekday and one weekend per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE)
Description: Based on the standardized lifestyle intervention mentioned by the calorie-restricted diet (CRD) intervention, TRE is administered to the study subjects in the intervention group. The eating window is limited to 12 hours per day, with the last meal no later than 7:00 p.m., and the study subjects are free to choose their eating window. Energy intake is not restricted during the eating period, and calorie-free, sugar-free beverages (water, tea, coffee) are allowed during the fasting period. A daily food diary will be kept for at least one weekday and one weekend per week.
Study: NCT06242418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: Eight cycles of FOLFOXIRI: Oxaliplatin 85mg/m2 ivgtt over 2 hours on day 1, Irinotecan 165mg/m2 ivgtt over 90 minutes on day 1, Calcium folinate 400mg/m2 ivgtt over 2 hours on day 1, 5-Fluorouracil 2400mg/m2 civ48h; Each cycle lasts for 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX
Description: Five cycles of XELOX: Oxaliplatin 130mg/m2 on day 1, Capecitabine 1000mg/m2 bid from day 1 to day 14; Each cycle lasts for 3 weeks.
Study: NCT05112289

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Brain Neuroimaging
Description: Non-invasive magnetic resonance imaging sequences will investigate metabolic signatures unique to migraine WMH. Imaging data will be used for development of artificial intelligence (AI) algorithms to classify the cause of WMHs.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Brain Neuroimaging
Description: Non-invasive magnetic resonance imaging sequences will investigate metabolic signatures unique to migraine WMH. Imaging data will be used for development of artificial intelligence (AI) algorithms to classify the cause of WMHs.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Brain Neuroimaging
Description: Non-invasive magnetic resonance imaging sequences will investigate metabolic signatures unique to migraine WMH. Imaging data will be used for development of artificial intelligence (AI) algorithms to classify the cause of WMHs.
Study: NCT06066528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Survodutide
Description: once weekly subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Survodutide
Description: once weekly subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once weekly subcutaneous injection
Study: NCT06648161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Labor Mirror
Description: The labor mirror used in the second stage of labor allows the mother and midwife to observe the descent and birth of the baby during vaginal delivery and provides instant visualization of progress for the mother and midwife, especially in water births or water births
Study: NCT05256771

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMS
Description: Abdominal muscle stimulation using EMS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMS
Description: Abdominal muscle stimulation using EMS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMS
Description: Abdominal muscle stimulation using EMS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1064 nm diode laser
Description: Adipose tissue heating using 1064 nm diode laser

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RF/PEMF
Description: Collagen re-modelling and reduction in subcutaneous fat using RF/PEMF
Study: NCT06109272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livmoniplimab
Description: Intravenous (IV) Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livmoniplimab
Description: Intravenous (IV) Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livmoniplimab
Description: Intravenous (IV) Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: Intravenous (IV) Solution
Study: NCT05256771

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RF/PEMF
Description: Collagen re-modelling and reduction in subcutaneous fat using RF/PEMF
Study: NCT05274308

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Blood sampling from all eligible transplantation patients according to the protocol
Study: NCT06109272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: Intravenous (IV) Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: Intravenous (IV) Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Intravenous (IV) Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Intravenous (IV) Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Intravenous (IV) Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Intravenous (IV) Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tremelimumab
Description: Intravenous (IV) Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tremelimumab
Description: Intravenous (IV) Solution
Study: NCT05366218

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Antibody vaccination
Study: NCT05925114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-309309
Description: Administered as oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-309309
Description: Administered as oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-309309
Description: Administered as oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as an oral capsule that looks identical to S-309309 capsule
Study: NCT06177301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab combined with GX
Description: Tislelizumab：200mg vgtt，q3w；treatment until disease progression, patients withdrawal of informed, or intolerable toxicity.~Gemcitabine：1000mg/m2, vgtt, d1,8, q3w, repeat 4-6 cycles. Capecitabine: 1000mg/m2, bid，po, d1-14, q3; treatment until disease progression, patients withdrawal of informed, or intolerable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab combined with GP
Description: Tislelizumab: 200mg vgtt，q3w；treatment until disease progression, patients withdrawal of informed, or intolerable toxicity.~Gemcitabine: 1000mg/m2, vgtt, d1,8, q3w, repeat 4-6 cycles； Cisplatin: 80mg/m2, ivgtt, d1 (high-dose cisplatin antiemetic and hydration regimen), q3w，repeat 4 \~ 6 cycles.
Study: NCT05359185

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Wellness
Description: https://familywellness.com/

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Wellness
Description: https://familywellness.com/

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Career Coaching
Description: Individualized career coaching and employment services.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Planning
Description: Individualized financial planning services.
Study: NCT06083675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Administered as oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Administered as oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Administered as oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered as oral tablets.
Study: NCT04956263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YG1699
Description: YG1699 is a novel investigational dual inhibitor of sodium-dependent glucose cotransporters, SGLT1 and SGLT2, indicated as an adjunct to diet and exercise to improve glycemic control and weight loss in adults with T2DM. A subsequent indication will be developed for YG1699 to improve glycemic control in adults with T1DM.~The proposed dosage form is a yellow, film-coated tablet for oral administration. The proposed tablet strengths for the current clinical research are 5 mg and 25 mg. The tablets are packaged in high-density polyethylene (HDPE) bottles with HDPE caps and desiccant inserters. Each HDPE bottle contains 30 tablets of drug product.~The study drug YG1699 is manufactured by Youngene Therapeutics Inc., Ltd., China.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YG1699
Description: YG1699 is a novel investigational dual inhibitor of sodium-dependent glucose cotransporters, SGLT1 and SGLT2, indicated as an adjunct to diet and exercise to improve glycemic control and weight loss in adults with T2DM. A subsequent indication will be developed for YG1699 to improve glycemic control in adults with T1DM.~The proposed dosage form is a yellow, film-coated tablet for oral administration. The proposed tablet strengths for the current clinical research are 5 mg and 25 mg. The tablets are packaged in high-density polyethylene (HDPE) bottles with HDPE caps and desiccant inserters. Each HDPE bottle contains 30 tablets of drug product.~The study drug YG1699 is manufactured by Youngene Therapeutics Inc., Ltd., China.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Farxiga® is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Faxiga® is available as a film-coated tablet for oral administration containing the equivalent of 5 mg dapagliflozin as dapagliflozin propanediol and the following inactive ingredients: microcrystalline cellulose, anhydrous lactose, crospovidone, silicon dioxide, and magnesium stearate. In addition, the film coating contains the following inactive ingredients: polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and yellow iron oxide.
Study: NCT05510739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor-cognitive home exercise supported by eHealth technology
Description: 10-week, individualized and progressive exercise program targeting functional strength, cardiovascular fitness and physical activity levels. Cognitive exercises are incorporated with motor exercises as an adjunct to the intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individualized home exercise program
Description: Individualised home exercise program leaflet involving one initial instruction session. Written instructions involving dose and exercise progression. No support during the 10 week period.
Study: NCT06117202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music therapy
Description: The research is a thesis study aimed at determining the stress and anxiety levels of patients seeking in vitro fertilization, investigating influencing factors, and revealing the impact of pre-procedural music listening on these stress and anxiety levels.
Study: NCT05297253

Intervention type: DEVICE
Intervention: telescopic overdenture
Description: fixed implant retained prostheses
Study: NCT05449847

Intervention type: BIOLOGICAL
Intervention: Blood Sampling
Description: Blood sampling under a complete aseptic conditions

Intervention type: BIOLOGICAL
Intervention: Blood Sampling
Description: Blood sampling under a complete aseptic conditions